Hydrocortisone Activase (Hydrocortisone)

Hydrocortisone Activase is used in clinical practice for several endocrine and inflammatory conditions.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute adrenal crisis when rapid glucocorticoid effect is required.
• Adjunct treatment of inflammatory or autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, or severe dermatitis.
• Short‑term control of flare‑ups in chronic inflammatory diseases where systemic glucocorticoids are indicated.
• Temporary suppression of severe allergic reactions that do not respond to antihistamines alone.

• Hydrocortisone Activase exerts its effect by binding to intracellular glucocorticoid receptors, forming a receptor‑ligand complex that translocates to the nucleus. Once inside, the complex interacts with glucocorticoid response elements on DNA, modulating transcription of target genes. This results in reduced synthesis of prostaglandins, leukotrienes, and cytokines, and it also inhibits the activity of phospholipase A2, thereby decreasing inflammatory mediator production and dampening immune cell activation.

Like other systemic glucocorticoids, Hydrocortisone Activase may be associated with a range of adverse reactions that vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort, such as dyspepsia or nausea.
• Transient elevation of blood glucose levels, especially in patients with diabetes risk.
• Mood changes including irritability or mild insomnia.

Serious

• Signs of adrenal suppression or crisis on abrupt discontinuation.
• Severe allergic reaction manifesting as rash, swelling, or difficulty breathing.
• Opportunistic infections due to immune suppression.

When prescribing Hydrocortisone Activase, clinicians should evaluate patient history and monitor for conditions that could be worsened by systemic glucocorticoid exposure.

• Assess for pre‑existing diabetes, hypertension, or osteoporosis before initiating therapy.
• Use the lowest effective dose for the shortest duration required to control symptoms.
• Monitor blood pressure, blood glucose, and bone mineral density during prolonged treatment.
• Counsel patients on the risk of infection and advise prompt reporting of fever or unexplained illness.
• Avoid abrupt discontinuation; taper gradually to prevent adrenal insufficiency.
• Consider alternative therapies in pregnant or lactating women when possible.

Hydrocortisone Activase can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines, requiring attention to potential interactions.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce hydrocortisone plasma concentrations.
• High‑dose systemic immunosuppressants that could compound infection risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase gastrointestinal ulcer risk.
• Anticoagulants, such as warfarin, as glucocorticoids can affect coagulation parameters.
• Diabetic medications, because hydrocortisone may raise blood glucose and require dose adjustments.
• Vaccines, particularly live attenuated vaccines, may have reduced efficacy or safety concerns.